Incorporating high-throughput exposure predictions with dosimetry-adjusted in vitro bioactivity to inform chemical toxicity testing

Toxicological Sciences

Volumn 148, Issue 1, 2015, Pages 121-136

  Wetmore, Barbara A ^a   Wambaugh, John F ^b   Allen, Brittany ^a   Ferguson, Stephen S ^b,c,d   Sochaski, Mark A ^a   Setzer, R Woodrow ^b   Houck, Keith A ^b   Strope, Cory L ^a   Cantwell, Katherine ^a   Judson, Richard S ^b   LeCluyse, Edward ^a   Clewell, Harvey J ^a   Thomas, Russell S ^a,b   Andersen, Melvin E ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c Life Technologies Corporation   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

dosimetry; exposure assessment; in vitro in vivo extrapolation; Predictive toxicology; ToxCast

Indexed keywords

1,1,1 TRICHLORO 2 (2 CHLOROPHENYL) 2 (4 CHLOROPHENYL)ETHANE; 2 CHLORO 2 DEOXYADENOSINE; BUTYL PARABEN; CANDOXATRIL; CHLORPYRIFOS; COUMARIN; CRYSTAL VIOLET; DEOXYADENOSINE; DIELDRIN; DINOSEB; DIPHENHYDRAMINE; FLUTAMIDE; HALOPERIDOL; INDUSTRIAL CHEMICAL; MEVINOLIN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PARACETAMOL; PENTACHLOROPHENOL; PESTICIDE; PHENYTOIN; PROPYLTHIOURACIL; SALAZOSULFAPYRIDINE; TRIAMCINOLONE; UNCLASSIFIED DRUG; VOLINANSERIN; ZAMIFENACIN; PLASMA PROTEIN;

ARTICLE; BIOLOGICAL ACTIVITY; DOSIMETRY; ELECTRON CAPTURE DETECTION; FLUORESCENCE; GAS CHROMATOGRAPHY; HEPATIC CLEARANCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; METABOLIC CLEARANCE; MONTE CARLO METHOD; PLASMA PROTEIN BINDING; TOXICITY TESTING; ADULT; BAYES THEOREM; BIOLOGICAL MODEL; CACO-2 CELL LINE; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CYTOLOGY; DRUG EFFECTS; FEMALE; GOVERNMENT; INTESTINE ABSORPTION; INTESTINE CELL; LIVER CELL; MALE; METABOLISM; PHARMACOKINETICS; PRECLINICAL STUDY; PROCEDURES; RISK ASSESSMENT; STANDARDS; TOXICOKINETICS; TRENDS; UNITED STATES;

ADULT; BAYES THEOREM; BLOOD PROTEINS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; ENTEROCYTES; FEMALE; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; PHARMACOKINETICS; RISK ASSESSMENT; TOXICITY TESTS; TOXICOKINETICS; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 84941893770     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv171     Document Type: Article

References (95)

1. Adeleye, Y., Andersen, M., Clewell, R., Davies, M., Dent, M., Edwards, S., Fowler, P., Malcomber, S., Nicol, B., Scott, A., et al. (2015). Implementing toxicity testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. Toxicol. 332, 102-111.
2. Adkison, K. K., Vaidya, S. S., Lee, D. Y., Koo, S. H., Li, L., Mehta, A. A., Gross, A. S., Polli, J. W., Humphreys, J. E., Lou, Y., et al. (2010). Oral sulfasalazine as a clinical BCRP probe substrate: Pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J. Pharm. Sci. 99, 1046-1062.
3. Akaike, H. (1974). A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19, 716-723.
4. Albert, K. S., Hallmark, M. R., Sakmar, E., Weidler, D. J., and Wagner, J. G. (1975). Pharmacokinetics of diphenhydramine in man. J. Pharmacokinet. Biopharm. 3, 159-170.
5. Andree, B., Nyberg, S., Ito, H., Ginovart, N., Brunner, F., Jaquet, F., Halldin, C., and Farde, L. (1998). Positron emission tomographic analysis of dose-dependent MDL 100, 907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J. Clin. Psychopharmacol. 18, 317-323.
6. Anjum, S., Swan, S. K., Lambrecht, L. J., Radwanski, E., Cutler, D. L., Affrime, M. B., and Halstenson, C. E. (1999). Pharmacokinetics of flutamide in patients with renal insufficiency. Br. J. Clin. Pharmacol. 47, 43-47.
7. Argenti, D., Jensen, B. K., Hensel, R., Bordeaux, K., Schleimer, R., Bickel, C., and Heald, D. (2000). A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol. 40, 770-780.
8. Arnot, J. A., Mackay, D., Webster, E., and Southwood, J. M. (2006). Screening level risk assessment model for chemical fate and effects in the environment. Environ. Sci. Technol. 40, 2316-2323.
9. Attene-Ramos, M. S., Miller, N., Huang, R., Michael, S., Itkin, M., Kavlock, R. J., Austin, C. P., Shinn, P., Simeonov, A., Tice, R. R., et al. (2013). The Tox21 robotic platform for the assessment of environmental chemicals-from vision to reality. Drug Discov. Today 18, 716-723.
10. Barter, Z. E., Bayliss, M. K., Beaune, P. H., Boobis, A. R., Carlile, D. J., Edwards, R. J., Houston, J. B., Lake, B. G., Lipscomb, J. C., Pelkonen, O. R., et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8, 33-45.
11. Beaumont, K. C., Causey, A. G., Coates, P. E., and Smith, D. A. (1996). Pharmacokinetics and metabolism of zamifenacin in mouse, rat, dog and man. Xenobiotica 26, 459-471.
12. Blyden, G. T., Greenblatt, D. J., Scavone, J. M., and Shader, R. I. (1986). Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J. Clin. Pharmacol. 26, 529-533.
13. Bramer, S. L., Brisson, J., Corey, A. E., and Mallikaarjun, S. (1999). Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers. Clin. Pharmacokinet. 37(Suppl. 2), 69-77.
14. Brien, J. F., Inaba, T., and Kalow, W. (1975). Comparative drug elimination in man-diphenylhydantoin and amobarbital. Eur. J. Clin. Pharmacol. 9, 79-83.
15. Calafat, A. M. (2012). The U.S. National Health and Nutrition Examination Survey and human exposure to environmental chemicals. Int. J. Hyg. Environ. Health 215, 99-101.
16. Cockcroft, D. W., and Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41.
17. Cox, L. A., Popken, D., Marty, M. S., Rowlands, J. C., Patlewicz, G., Goyak, K. O., and Becker, R. A. (2014). Developing scientific confidence in HTS-derived prediction models: Lessons learned from an endocrine case study. Regul. Toxicol. Pharmacol. 69, 443-450.
18. Critchley, J. A., Critchley, L. A., Anderson, P. J., and Tomlinson, B. (2005). Differences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. J. Clin. Pharm. Ther. 30, 179-184.
19. Davies, B., and Morris, T. (1993). Physiological parameters in laboratory animals and humans. Pharm. Res. 10, 1093-1095.
20. Derendorf, H., Hochhaus, G., Rohatagi, S., Mollmann, H., Barth, J., Sourgens, H., and Erdmann, M. (1995). Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J. Clin. Pharmacol. 35, 302-305.
21. Dionisio, K. L., Frame, A. M., Goldsmith, M.-R., Wambaugh, J. F., Liddell, A., Cathey, T., Smith, D., Vail, J., Ernstoff, A. S., and Fantke, P. (2015). Exploring consumer exposure pathways and patterns of use for chemicals in the environment. Toxicol. Reports 2, 228-237.
22. Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R. W., and Kavlock, R. J. (2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95, 5-12.
23. Doser, K., Guserle, R., Kramer, R., Laufer, S., and Lichtenberger, K. (1997). Bioequivalence evaluation of two flutamide preparations in healthy female subjects. Arzneimittelforschung 47, 213-217.
24. Ferry, A., Jaillon, P., Lecocq, B., Lecocq, V., and Jozefczak, C. (1989). Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers. Fundam. Clin. Pharmacol. 3, 383-392.
25. Gelotte, C. K., Auiler, J. F., Lynch, J. M., Temple, A. R., and Slattery, J. T. (2007). Disposition of acetaminophen at 4, 6, and 8 g/day for 3 days in healthy young adults. Clin. Pharmacol. Ther. 81, 840-848.
26. Giles, H. G., Roberts, E. A., Orrego, H., and Sellers, E. M. (1981). Disposition of intravenous propylthiouracil. J. Clin. Pharmacol. 21, 466-471.
27. Goldsmith, M. R., Grulke, C. M., Brooks, R. D., Transue, T. R., Tan, Y. M., Frame, A., Egeghy, P. P., Edwards, R., Chang, D. T., Tornero-Velez, R., et al. (2014). Development of a consumer product ingredient database for chemical exposure screening and prioritization. Food Chem. Toxicol. 65, 269-279.
28. Gu, G. Z., Xia, H. M., Pang, Z. Q., Liu, Z. Y., Jiang, X. G., and Chen, J. (2011). Determination of sulphasalazine and its main metabolite sulphapyridine and 5-aminosalicylic acid in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879, 449-456.
29. Hallifax, D., Foster, J. A., and Houston, J. B. (2010). Prediction of human metabolic clearance from in vitro systems: Retrospective analysis and prospective view. Pharm. Res. 27, 2150-2161.
30. Hochhaus, G., Portner, M., Barth, J., Mollmann, H., and Rohdewald, P. (1990). Oral bioavailability of triamcinolone tablets and a triamcinolone diacetate suspension. Pharm. Res. 7, 558-560.
31. Houck, K. A., Dix, D. J., Judson, R. S., Kavlock, R. J., Yang, J., and Berg, E. L. (2009). Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen 14, 1054-1066.
32. Houston, J. B., Rowland-Yeo, K., and Zanelli, U. (2012). Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility. Toxicol. In Vitro 26, 1265-1271.
33. Huang, R., Xia, M., Cho, M. H., Sakamuru, S., Shinn, P., Houck, K. A., Dix, D. J., Judson, R. S., Witt, K. L., Kavlock, R. J., et al. (2011). Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ. Health Perspect. 119, 1142-1148.
34. Imai, T., and Ohura, K. (2010). The role of intestinal carboxylesterase in the oral absorption of prodrugs. Curr. Drug Metab. 11, 793-805.
35. Isaacs, K. K., Glen, W. G., Egeghy, P., Goldsmith, M. R., Smith, L., Vallero, D., Brooks, R., Grulke, C. M., and Ozkaynak, H. (2014). SHEDS-HT: An integrated probabilistic exposure model for prioritizing exposures to chemicals with near-field and dietary sources. Environ. Sci. Technol. 48, 12750-12759.
36. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., and Rostami-Hodjegan, A. (2009). The Simcyp((R)) populationbased ADME simulator. Expert. Opin. Drug Metab. Toxicol. 5, 211-223.
37. Johnson, T. N., Tucker, G. T., Tanner, M. S., and Rostami-Hodjegan, A. (2005). Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl. 11, 1481-1493.
38. Judson, R., Richard, A., Dix, D. J., Houck, K., Martin, M., Kavlock, R., Dellarco, V., Henry, T., Holderman, T., Sayre, P., et al. (2009). The toxicity data landscape for environmental chemicals. Environ. Health Perspect. 117, 685-695.
39. Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M., et al. (2010). In vitro screening of environmental chemicals for targeted testing prioritization: The ToxCast project. Environ. Health Perspect. 118, 485-492.
40. Judson, R. S., Kavlock, R. J., Setzer, R. W., Cohen Hubal, E. A., Martin, M. T., Knudsen, T. B., Houck, K. A., Thomas, R. S., Wetmore, B. A., and Dix, D. J. (2011). Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 24, 451-462.
41. Kabanda, L., Lefebvre, R. A., and Remon, J. P. (1996). In-vivo evaluation in man of a hydrophilic matrix containing propylthiouracil. J. Pharm. Pharmacol. 48, 1023-1026.
42. Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N., Knudsen, T., Martin, M., Padilla, S., Reif, D., Richard, A., et al. (2012). Update on EPA's ToxCast program: Providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol. 25, 1287-1302.
43. Kavlock, R. J., Austin, C. P., and Tice, R. R. (2009). Toxicity testing in the 21st century: Implications for human health risk assessment. Risk Anal. 29, 485-487; discussion 492-497.
44. Kaye, B., Brearley, C. J., Cussans, N. J., Herron, M., Humphrey, M. J., and Mollatt, A. R. (1997). Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica 27, 1091-1102.
45. Kilford, P. J., Gertz, M., Houston, J. B., and Galetin, A. (2008). Hepatocellular binding of drugs: Correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab. Dispos. 36, 11941197.
46. Kleinstreuer, N. C., Judson, R. S., Reif, D. M., Sipes, N. S., Singh, A. V., Chandler, K. J., Dewoskin, R., Dix, D. J., Kavlock, R. J., and Knudsen, T. B. (2011). Environmental impact on vascular development predicted by high throughput screening. Environ. Health Perspect. 119, 1596-1603.
47. Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. M., Judson, R. S., Polokoff, M., Dix, D. J., et al. (2014). Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 32, 583-591.
48. Knight, A. W., Little, S., Houck, K., Dix, D., Judson, R., Richard, A., McCarroll, N., Akerman, G., Yang, C., Birrell, L., et al. (2009). Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. Regul. Toxicol. Pharmacol. 55, 188-199.
49. Knudsen, T. B., Houck, K. A., Sipes, N. S., Singh, A. V., Judson, R. S., Martin, M. T., Weissman, A., Kleinstreuer, N. C., Mortensen, H. M., Reif, D. M., et al. (2011). Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets. Toxicology 282, 1-15.
50. Kobayashi, Y., Fukami, T., Shimizu, M., Nakajima, M., and Yokoi, T. (2012). Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. Drug Metab. Dispos. 40, 1080-1084.
51. Kothare, P. A., Linnebjerg, H., Skrivanek, Z., Reddy, S., Mace, K., Pena, A., Han, J., Fineman, M., and Mitchell, M. (2007). Exenatide effects on statin pharmacokinetics and lipid response. Int. J. Clin. Pharmacol. Ther. 45, 114-120.
52. Krewski, D., Westphal, M., Andersen, M. E., Paoli, G. M., Chiu, W. A., Al-Zoughool, M., Croteau, M. C., Burgoon, L. D., and Cote, I. (2014). A framework for the next generation of risk science. Environ. Health Perspect. 122, 796-805.
53. Lamiable, D., Vistelle, R., Trenque, T., Fay, R., Millart, H., and Choisy, H. (1993). Sensitive high-performance liquid chromatographic method for the determination of coumarin in plasma. J. Chromatogr. 620, 273-277.
54. Landesmann, B., Mennecozzi, M., Berggren, E., and Whelan, M. (2013). Adverse outcome pathway-based screening strategies for an animal-free safety assessment of chemicals. Altern. Lab. Anim. 41, 461-471.
55. Li, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E., and Silber, P. M. (1999). Cryopreserved human hepatocytes: Characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 121, 17-35.
56. Lindemalm, S., Savic, R. M., Karlsson, M. O., Juliusson, G., Liliemark, J., and Albertioni, F. (2005). Application of population pharmacokinetics to cladribine. BMC Pharmacol. 5, 4.
57. Luna, B. G., Scavone, J. M., and Greenblatt, D. J. (1989). Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. J. Clin. Pharmacol. 29, 257-260.
58. Ma, J. J., Liu, C. G., Li, J. H., Cao, X. M., Sun, S. L., and Yao, X. (2009). Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin. Chim. Acta 407, 30-35.
59. Martin, M. T., Dix, D. J., Judson, R. S., Kavlock, R. J., Reif, D. M., Richard, A. M., Rotroff, D. M., Romanov, S., Medvedev, A., Poltoratskaya, N., et al. (2010). Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem. Res. Toxicol. 23, 578-590.
60. Martin, M. T., Knudsen, T. B., Reif, D. M., Houck, K. A., Judson, R. S., Kavlock, R. J., and Dix, D. J. (2011). Predictive model of rat reproductive toxicity from ToxCast high throughput screening. Biol. Reprod. 85, 327-339.
61. McMullen, P. D., Bhattacharya, S., Woods, C.G., Sun, B., Yarborough, K., Ross, S.M., Miller, M.E., McBride, M.T., LeCluyse, E.L., Clewell, R.A., et al. (2014). A map of the PPARa transcription regulatory network for primary human hepatocytes. Chem. Biol. Interact. 209, 14-24.
62. Mennecozzi, M., Landesmann, B., Harris, G.A., Liska, R., and Whelan, M. (2012). Hepatotoxicity screening taking a modeof-action approach using HepaRG cells and HCA. ALTEX 1, 193-204.
63. Mielke, H., Abraham, K., Gotz, M., Vieth, B., Lampen, A., Luch, A., and Gundert-Remy, U. (2011). Physiologically based toxicokinetic modelling as a tool to assess target organ toxicity in route-to-route extrapolation-the case of coumarin. Toxicol. Lett. 202, 100-110.
64. Mignini, F., Tomassoni, D., Streccioni, V., Traini, E., and Amenta, F. (2008). Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers. Clin. Exp. Hypertens 30, 95-108.
65. Morgan, J. A., and Tatar, J. F. (1972). Calculation of the residual sum of squares for all possible regressions. Technometrics 14, 317-325.
66. Nolan, R. J., Freshour, N. L., Kastl, P. E., and Saunders, J. H. (1984). Pharmacokinetics of picloram in male volunteers. Toxicol. Appl. Pharmacol. 76, 264-269.
67. NRC. (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Research Council of the National Academies, Washington, D.C.
68. Pastrello, C., Pasini, E., Kotlyar, M., Otasek, D., Wong, S., Sangrar, W., Rahmati, S., and Jurisica, I. (2014). Integration, visualization and analysis of human interactome. Biochem. Biophys. Res. Commun. 445, 757-773.
69. Pelkonen, O., Turpeinen, M., Hakkola, J., Abass, K., Pasanen, M., Raunio, H., and Vahakangas, K. (2013). Preservation, induction or incorporation of metabolism into the in vitro cellular system-views to current opportunities and limitations. Toxicol. In Vitro 27, 1578-1583.
70. Pleil, J. D., Stiegel, M. A., Madden, M. C., and Sobus, J. R. (2011). Heat map visualization of complex environmental and biomarker measurements. Chemosphere 84, 716-723.
71. Plyte, S. E., Hughes, K., Nikolakaki, E., Pulverer, B. J., andWoodgett, J. R. (1992). Glycogen synthase kinase-3: Functions in oncogenesis and development. Biochim. Biophys. Acta 1114, 147-162.
72. Radwanski, E., Perentesis, G., Symchowicz, S., and Zampaglione, N. (1989). Single and multiple dose pharmacokinetic evaluation of flutamide in normal geriatric volunteers. J. Clin. Pharmacol. 29, 554-558.
73. Reif, D. M., Sypa, M., Lock, E. F., Wright, F. A., Wilson, A., Cathey, T., Judson, R. R., and Rusyn, I. (2013). ToxPi GUI: An interactive visualization tool for transparent integration of data from diverse sources of evidence. Bioinformatics 29, 402-403.
74. Rosenbaum, R. K., Bachmann, T. M., Swirsky Gold, L., Huijbregts, M. A. J., Jolliet, O., Juraske, R., Koehler, A., Larsen, H.F., MacLeod, M., Margni, M., et al. (2008). USEtox-The UNEPSETAC toxicity model: Recommended characterization factors for human toxicity and freshwater ecotoxicity in life cycle impact assessment. Int. J.Life Cycle Assess. 13, 532-546.
75. Rostami-Hodjegan, A., Shiran, M. R., Tucker, G. T., Conway, B. R., Irwin, W. J., Shaw, L. R., and Grattan, T. J. (2002). A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro/in vivo correlation. Drug Dev. Ind. Pharm. 28, 533-543.
76. Rotroff, D. M., Beam, A. L., Dix, D. J., Farmer, A., Freeman, K. M., Houck, K. A., Judson, R. S., LeCluyse, E. L., Martin, M. T., Reif, D. M., et al. (2010a). Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J. Toxicol. Environ. Health B.-Crit. Rev. 13, 329-346.
77. Rotroff, D. M., Dix, D. J., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Reif, D. M., Richard, A. M., Sipes, N. S., Abassi, Y. A., et al. (2013). Real-time growth kinetics measuring hormone mimicry for ToxCast chemicals in T-47D human ductal carcinoma cells. Chem. Res. Toxicol. 26, 1097-1107.
78. Rotroff, D. M., Wetmore, B. A., Dix, D. J., Ferguson, S. S., Clewell, H. J., Houck, K. A., Lecluyse, E. L., Andersen, M. E., Judson, R. S., Smith, C. M., et al. (2010b). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 117, 348-358.
79. Sipes, N. S., Martin, M. T., Kothiya, P., Reif, D. M., Judson, R. S., Richard, A. M., Houck, K. A., Dix, D. J., Kavlock, R. J., and Knudsen, T. B. (2013). Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem. Res. Toxicol. 26, 878-895.
80. Sipes, N. S., Martin, M. T., Reif, D. M., Kleinstreuer, N. C., Judson, R. S., Singh, A. V., Chandler, K. J., Dix, D. J., Kavlock, R. J., and Knudsen, T. B. (2011). Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol. Sci. 124, 109-127.
81. Smith, C. M., Nolan, C. K., Edwards, M. A., Hatfield, J. B., Stewart, T. W., Ferguson, S. S., Lecluyse, E. L., and Sahi, J. (2012). A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions andmonolayer cultures of cryopreserved primary human hepatocytes. J. Pharm. Sci. 101, 3989-4002.
82. Tan, Y. M., Liao, K. H., and Clewell, H. J., III. (2007). Reverse dosimetry: Interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expo. Sci. Environ. Epidemiol. 17, 591-603.
83. Thomas, R. S., Black, M. B., Li, L., Healy, E., Chu, T. M., Bao, W., Andersen, M. E., and Wolfinger, R. D. (2012). A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. 128, 398-417.
84. Thomas, R. S., Philbert, M. A., Auerbach, S. S., Wetmore, B. A., Devito, M. J., Cote, I., Rowlands, J. C., Whelan, M. P., Hays, S. M., Andersen, M. E., et al. (2013). Incorporating new technologies into toxicity testing and risk assessment: Moving from 21st century vision to a data-driven framework. Toxicol. Sci. 136, 4-18.
85. Toothaker, R. D., Barker, S. H., Gillen, M. V., Helsinger, S. A., Kindberg, C. G., Hunt, T. L., and Powell, J. H. (2000). Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride. Biopharm. Drug Dispos. 21, 229-233.
86. Tukey, J. W. (1977). Exploratory Data Analysis. Addison-Wesley, Reading, MA.
87. Wambaugh, J. F., Setzer, R. W., Reif, D. M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J. A., Joliet, O., Frame, A., Rabinowitz, J., Knudsen, T. B., et al. (2013). High-throughput models for exposure-based chemical prioritization in the ExpoCast project. Environ. Sci. Technol. 47, 8479-8488.
88. Wambaugh, J. F., Wang, A., Dionisio, K. L., Frame, A., Egeghy, P., Judson, R., and Setzer, R. W. (2014). High throughput heuristics for prioritizing human exposure to environmental chemicals. Environ. Sci. Technol. 48, 12760-12767.
89. Waters, N. J., Jones, R., Williams, G., and Sohal, B. (2008). Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 97, 4586-4595.
90. Wetmore, B.A. (2015). Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. Toxicology 332, 94-101.
91. Wetmore, B. A., Wambaugh, J. F., Ferguson, S. S., Li, L., Clewell, H. J., III, Judson, R. S., Freeman, K., Bao, W., Sochaski, M. A., Chu, T. M., et al. (2013). Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol. Sci. 132, 327-346.
92. Wetmore, B. A., Wambaugh, J. F., Ferguson, S. S., Sochaski, M. A., Rotroff, D. M., Freeman, K., Clewell, H. J., III, Dix, D. J., Andersen, M. E., Houck, K. A., et al. (2012). Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 125, 157-174.
93. Whitlam, J. B., and Brown, K. F. (1981). Ultrafiltration in serum protein binding determinations. J. Pharm. Sci. 70, 146-150.
94. Yasui-Furukori, N., Kondo, T., Mihara, K., Suzuki, A., Inoue, Y., De Vries, R., and Kaneko, S. (2002). Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J. Clin. Pharmacol. 42, 1083-1088.
95. Zhang, X., Arnot, J. A., and Wania, F. (2014). Model for screeninglevel assessment of near-field human exposure to neutral organic chemicals released indoors. Environ. Sci. Technol. 48, 12312-12319.